Short-course radiotherapy in elderly patients with glioblastoma: Feasibility and efficacy of results from a single centre

Research output: Contribution to journalArticlepeer-review


Background: The incidence of glioblastoma (GBM) in the elderly population is currently increasing, with a peak seen between 65 and 84 years. The optimal treatment in terms of both efficacy and quality of life still remains a relevant and debated issue today. The purpose of our study was to evaluate the feasibility of short-course hypofractionated accelerated radiotherapy (HART) in GBM patients aged over 70 years and with a good Karnofsky performance score (KPS). Methods: A review of medical records at the "Istituto Neurologico C. Besta" was undertaken; patients aged ≥ 70 years who had undergone adjuvant HART for GBM between January 2000 and January 2004 were included in the study. HART was administered to a total dose of 45 Gy, 2.5 Gy/fraction, in three daily fractions for three consecutive days/cycle fractions each, delivered in two cycles (split 15 days). Results: A total of 33 patients were evaluable for the current analysis. Median follow-up was 10 months. According to CTCAE (version 3.0) criteria, none of the patients developed radiation-induced neurological status deterioration or necrosis. KPS evaluation after HART was found to be stable in 73 % of patients, improved in 24 %, and worse in 3 %. The median overall survival time of the entire study population was 8 months (range 2-24). Conclusions: Our findings suggest that a hypofractionated accelerated schedule can be a safe and effective option in the treatment of GBM in the elderly.

Original languageEnglish
Pages (from-to)456-461
Number of pages6
JournalStrahlentherapie und Onkologie
Issue number6
Publication statusPublished - Jun 2013


  • Elderly
  • Glioblastoma
  • Hypofractionated
  • Radiation therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology


Dive into the research topics of 'Short-course radiotherapy in elderly patients with glioblastoma: Feasibility and efficacy of results from a single centre'. Together they form a unique fingerprint.

Cite this